ALMIRALL (E2Z BE) stock market data APIs
€12.4394
0(0%)
as of October 31, 2025
Try our APIs with
free plan!
ALMIRALL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for E2Z.BE.
Prev. Close
12.4394
Open
12.4394
High
12.4394
Low
12.4394
52 wk Range
7.9417-12.64
Market Cap
1 925 M
Dividends (Yield)
0.0198
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ALMIRALL data using free add-ons & libraries
Get ALMIRALL Fundamental Data
ALMIRALL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ALMIRALL News
New
United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall
Company Logo The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...
RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER
Recordati NEWS RELEASE Milan, 23 October 2025 – Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, ...
Almirall (BME:ALM): Is the Recent Share Price Momentum Justified by Its Current Valuation?
Almirall (BME:ALM) shares have quietly advanced this month, gaining 7% over the past four weeks. Investors might be paying closer attention to the company’s fundamentals as the company shows steady ...
Can Almirall’s Strong 2025 Rally Continue After Positive Dermatology Pipeline Developments?
If you are wondering whether now is the right moment to make a move on Almirall, you are definitely not alone. Over the last year, Almirall’s stock has turned quite a few heads, climbing a remarkabl...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
